• PD98059 MEK Inhibitor: Workflows and Applications

  2026-08-12

  PD98059 provides reversible pharmacological control of MEK-to-ERK signaling for studies of cell-cycle arrest, apoptosis, oxidative injury, and neuroprotection. This practical guide connects pathway validation with reproducible dosing, readout selection, and troubleshooting across leukemia, liver-injury, and ischemia-related models.

• PF-562271 HCl: Designing Better FAK Assays

  2026-08-12

  PF-562271 HCl is a selective FAK/Pyk2 inhibitor for mechanistic cancer research. This guide applies cheminformatics-driven library design principles to improve target engagement studies, phosphorylation assays, and interpretation of tumor phenotypes.

• 2'3'-cGAMP (Sodium Salt) Workflow Guide

  2026-08-11

  Build reproducible cGAS-STING assays with 2'3'-cGAMP (sodium salt), from aqueous stock preparation and type I interferon induction to migration-focused phenotyping. The workflow also translates new evidence for a Rab18/FosB signaling branch into practical controls for immunology, cancer biology, and immunotherapy research.

• Gastrin I for GI Organoid Assay Design

  2026-08-11

  Gastrin I (human) provides a defined CCK2 receptor stimulus for dissecting gastric acid signaling, while hiPSC-derived intestinal organoids add a human-relevant platform for absorption and metabolism studies. This guide combines receptor pharmacology, organoid workflows, controls, and troubleshooting to help researchers build more interpretable gastrointestinal assays.

• CPI-613: Mitochondrial Metabolism Meets Ferroptosis

  2026-08-10

  CPI-613 is a lipoate-derived inhibitor of mitochondrial carbon metabolism that enables mechanistic cancer research. This article connects PDH and KGDH perturbation with calcium-dependent ferroptosis biology while defining practical boundaries for apoptosis assays and tumor cell metabolism studies.

• hiPSC Intestinal Organoids for Pharmacokinetics

  2026-08-09

  The reference study establishes a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. These organoids can be cryopreserved, expanded, and differentiated into epithelial monolayers containing metabolically and transporter-competent enterocytes, providing a more human-relevant platform for oral drug pharmacokinetic studies.

• Carbon-Ion Radiotherapy, DHODH, and Ferroptosis

  2026-08-08

  A 2025 Frontiers in Medicine study reports that carbon-ion radiotherapy suppresses gastric cancer growth by downregulating DHODH, increasing ferroptosis-associated stress, and promoting M1-like macrophage polarization. The work provides a preclinical mechanistic framework linking radiation quality, tumor-cell redox biology, and immune remodeling, while leaving clinical validation and broader model transferability unresolved.

• Gastrin I (human): Assay Reliability Guide

  2026-08-07

  Learn how Gastrin I (human), SKU B5358, can improve experimental control in CCK2 receptor, gastric acid secretion, organoid, viability, and cytotoxicity workflows. This scenario-based guide covers model selection, peptide handling, data interpretation, and practical vendor evaluation using product specifications and current organoid literature.

• Esculin’s Mechanisms in RCC: Apoptosis, PI3K/Akt, and Cell F

  2026-08-07

  This study presents the first systematic mechanistic analysis of esculin’s anti-tumor activity in renal cell carcinoma, revealing its impact on apoptosis and the PI3K/Akt pathway using network pharmacology and in vitro assays. These findings provide a rationale for further investigation of esculin in RCC therapy and highlight the importance of robust cell death detection strategies in cancer research.

• O-GlcNAcylation Controls Porcine Oocyte Maturation via Mitoc

  2026-08-06

  This study demonstrates that O-GlcNAcylation, a dynamic protein modification, is essential for porcine oocyte maturation by maintaining mitochondrial dynamics and function. Disruption of O-GlcNAc transferase impairs cytoskeletal organization and mitochondrial integrity, highlighting critical regulatory mechanisms in reproductive biology.

• ROS Assay Kit (DHE): Precision Superoxide Detection in Aging

  2026-08-06

  Explore how the Reactive Oxygen Species Assay Kit enables precise superoxide detection in living cells for oxidative stress and aging studies. This in-depth guide examines the dihydroethidium (DHE) probe, redox signaling, and innovative assay strategies—offering unique practical insights for apoptosis and osteoarthritis research.

• KPT330 Enhances CRISPR-Cas9 Editing Precision via mRNA Expor

  2026-08-05

  The study by Cui et al. demonstrates that selective inhibitors of nuclear export, notably the FDA-approved drug KPT330, can significantly improve the specificity of CRISPR-Cas9 genome and base editing by interfering with the export of Cas9 mRNA from the nucleus. This mechanistic insight provides a new strategy to mitigate off-target effects and optimize gene editing outcomes in mammalian systems.

• BIBR 1532: Precision Telomerase Inhibition and Advanced Assa

  2026-08-05

  Explore the scientific foundations and translational power of BIBR 1532, a leading telomerase inhibitor. This deep dive reveals unique assay strategies, mechanistic insights, and practical guidance for researchers innovating in cancer biology.

• Axitinib (AG 013736): Applied Protocols for Angiogenesis Ass

  2026-08-04

  Axitinib (AG 013736) empowers researchers to precisely dissect VEGF-driven mechanisms in angiogenesis and tumor growth inhibition workflows. This article delivers actionable protocols, advanced troubleshooting, and translational guidance for maximizing experimental success with this benchmark VEGFR inhibitor in both in vitro and in vivo models.

• Revealing Nonconventional GLP-1R and Glucagon Antagonist Int

  2026-08-04

  Chepurny et al. (2019) advanced the understanding of GLP-1 and glucagon receptor specificity by demonstrating that glucagon can act as a nonconventional GLP-1 receptor agonist, and that classically selective agonists and antagonists may have unexpected cross-reactivity. These findings, revealed using high-throughput FRET assays for cAMP, prompt a re-evaluation of peptide selectivity in metabolic regulation and type 2 diabetes research.

16330 records 1/1089 page Next 12345 下5页 Last page